1477 Stock Overview
Operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Ocumension Therapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.21 |
| 52 Week High | HK$7.41 |
| 52 Week Low | HK$3.62 |
| Beta | 0.81 |
| 1 Month Change | 9.22% |
| 3 Month Change | 30.90% |
| 1 Year Change | -25.36% |
| 3 Year Change | -51.67% |
| 5 Year Change | n/a |
| Change since IPO | -85.92% |
Recent News & Updates
Recent updates
Ocumension Therapeutics (HKG:1477) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Apr 02
Investors Still Waiting For A Pull Back In Ocumension Therapeutics (HKG:1477)
Jan 27With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For
Sep 21Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results
Aug 15We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now
Jun 13Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable
Apr 29Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation
Mar 14Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates
Aug 29We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely
Jul 13Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount?
Jun 02We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate
Jan 20We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate
Sep 27Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful?
Jan 23
Shareholder Returns
| 1477 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -3.2% | -2.5% | 2.1% |
| 1Y | -25.4% | 5.2% | 12.6% |
Return vs Industry: 1477 underperformed the Hong Kong Pharmaceuticals industry which returned 4.1% over the past year.
Return vs Market: 1477 underperformed the Hong Kong Market which returned 13% over the past year.
Price Volatility
| 1477 volatility | |
|---|---|
| 1477 Average Weekly Movement | 9.1% |
| Pharmaceuticals Industry Average Movement | 7.6% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in HK Market | 15.5% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 1477 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1477's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 489 | Victor Liu | www.ocumension.com |
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis.
Ocumension Therapeutics Fundamentals Summary
| 1477 fundamental statistics | |
|---|---|
| Market cap | HK$4.24b |
| Earnings (TTM) | -HK$290.39m |
| Revenue (TTM) | HK$451.70m |
9.4x
P/S Ratio-14.6x
P/E RatioIs 1477 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1477 income statement (TTM) | |
|---|---|
| Revenue | CN¥417.31m |
| Cost of Revenue | CN¥192.24m |
| Gross Profit | CN¥225.07m |
| Other Expenses | CN¥493.34m |
| Earnings | -CN¥268.27m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 53.93% |
| Net Profit Margin | -64.29% |
| Debt/Equity Ratio | 0.4% |
How did 1477 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/13 03:49 |
| End of Day Share Price | 2025/05/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ocumension Therapeutics is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yanyin Zhu | China International Capital Corporation Limited |
| Fang Quan | China International Capital Corporation Limited |
| Ziyi Chen | Goldman Sachs |